Introduction
Tramadol hydrochloride is a synthetic analogue of codeine which can bind to µ-opioid receptors and inhibit nor-epinephrine and serotonin uptake. 1 It has been approved by the Food and Drug Administration 
Indications for use of tramadol
• Treatment of moderate to severe pain (post-operative pain; lumbar or sacral pain; articular or rheumatic pain; cervical or brachial pain; pain from contusions, crushes, strains, or sprains; pain from tumours or metastases; neuralgia)
Contraindications to tramadol use • Allergy to tramadol
• Acute intoxication with alcohol, hypnotics, centrally acting analgesics, opiate agonists, or psychotropics
• History of epilepsy or seizures
• Allergy to codeine
• Previous dependence on opiate agonists or tendency towards drug abuse for use in the management of moderate to severe pain since 1995. Criteria for the use of tramadol have also been published (Table 1) . 2 It has not been classified as a controlled drug because of its low abuse potential. Its use can also avoid the side effects of non-steroidal anti-inflammator y drugs (NSAID), which are commonly prescribed for pain control in emergency departments. However, this drug has not been widely used in the emergency setting since its introduction in Hong Kong. The aims of this pilot study were to evaluate the application of tramadol in the emergency department setting and to assess its efficacy and safety.
Materials and methods
Patients at or above 16 years of age with moderate to severe pain were recruited if they fit in the following categories: (1) acute musculoskeletal pain irrespective of trauma status; (2) acute arthritis including gout; (3) renal colic; (4) dental pain and (5) dysmenorrhoea. Exclusion criteria included known hypersensitivity to tramadol, active malignancy, opioid dependence, major renal or hepatic dysfunction, current psychiatric drugs treatment, pregnancy or lactation, recent major head injury and acute alcohol intoxication.
The primary end-point of the study was pain control. It was assessed by a self-completed questionnaire with a 10 cm visual analogue scale (VAS) before injection, 30 minutes and 60 minutes after the injection of tramadol. The second end-point was complication related to the use of tramadol. The duty nurses would ask the patients on a checklist for possible related side effects at the end of the study. The blood pressure, pulse rate, oxygen saturation and respiratory rate were also recorded accordingly.
All patients received 100 mg intramuscular tramadol. No other form of pharmacologic analgesics was given in the first hour after injection. All rescue analgesics required after the first hour were recorded. Side effects related to the drug were documented and included in the secondary end-point assessment.
The change in the VAS and vital sign parameters were analysed by the paired t-test using the Statistical Package for Social Science, Version 9.0. A p-value less than 0.05 was considered as statistically significant.
Results
There were forty patients recruited from 1 October 2002 to 31 December 2002. Twenty-four (60%) were male. Their age ranged from 18 to 85 years (mean age: 53.5). More than half of the patients required analgesics because of acute musculoskeletal pain ( Figure 1 ).
There was significant reduction in pain after injection of tramadol. The effect was more prominent at 60 minutes than 30 minutes after injection (3.38 vs 1.90) ( Table 2 ). There were also statistically significant drops in mean blood pressure and pulse rate after tramadol, but the magnitudes were not clinically significant. There was no difference in the oxygen saturation and respiratory rate before and after the injection of tramadol. A total of eight patients reported side effects. The total incidence was 20% but they were all minor. Three of them vomited after tramadol and three more patients complained of nausea. Dizziness and dry mouth were reported by two patients. Seven patients required rescue analgesics including dologesic and NSAID.
Three patients were admitted afterwards. One patient suffered from fractured medial malleolus of ankle. She was transferred to a private hospital for operation upon her request. The second one presented with neck pain and showed no significant improvement after tramadol. She was discovered to have hypotension after five hours of observation. The last patient suffered from back contusion and blunt abdominal trauma. All were finally discharged uneventfully.
Discussion
Tramadol hydrochloride is a synthetic analogue of codeine that has low affinity for µ-opiate receptors and can inhibit nor-epinephrine and serotonin uptake. Its onset of action is in the range of minutes with parenteral injection, with effect usually reaching the maximum within 15 to 30 minutes and lasting for 3 to 6 hours. Respiratory depression is one of the major concerns of opioids. However, it was found that tramadol had no significant effect on respiratory rate, minute volume of ventilation, oxygen saturation and arterial blood gas when compared to placebo. 3 It has also low abuse potential and is not considered as a controlled drug.
Its analgesic efficacy has already been widely studied overseas but most of the studies used intravenous tramadol for post-operative pain control. No study has been done primarily on the intramuscular route in the emergency setting. Previous data showed that tramadol was as effective as intravenous morphine and better than ketorolac in the management of postoperative pain. 4, 5 Eray et al found that intravenous tramadol was also effective in pain control for renal colic. 6 In the pre-hospital setting, Vergnion et al reported similar efficacy of tramadol and morphine administered intravenously in the management of pain in trauma patients. 7 The analgesic effect of oral tramadol was comparable with oral diclofenac. 8 However, oral tramadol was not superior to hydrocodone-acetaminophen in the management of acute musculoskeletal pain in the emergency setting. 9 Our study provided initial data supporting the use of intramuscular tramadol in the emergency department. However, we cannot answer whether tramadol is better than NSAID in the management of acute pain. Further randomised double-blind studies are necessary to address on this issue.
The commonest side effects of tramadol are nausea, dizziness, drowsiness, sweating, vomiting and dry mouth. The reported incidence was about 1.6 to 6.1%. 10 Tramadol would not delay gastric emptying in analgesic dose. 11 Cases of seizure after consumption of tramadol have been reported. 12 Most of them were related to concomitant medications including tricyclic anti-depressants and serotonin reuptake inhibitors and death could be a consequence. 13 Other potential side effects include mania, auditory hallucination and serotonin syndrome. [14] [15] [16] Though it is claimed to have a low abuse potential, withdrawal syndrome after chronic use has been reported. 17, 18 In our series, though the incidence of side effect was higher than overseas studies, they were all minor.
Conclusion
Our pilot study showed that tramadol was a safe drug in the emergency setting, especially when NSAID was contraindicated. It was effective in pain control in most cases. The side effects were only minor. However, we could not answer whether it was more efficacious than NSAID. Further double-blind studies are required to explore on the topic.
